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INTRODUCTION
As colonoscopy with the removal of precancerous lesions is considered the gold standard modality in the prevention of colorectal cancer (CRC) (1), concerns were raised by studies showing limited effectiveness of colonoscopy in the proximal colon (2) (3) (4) . The serrated neoplastic pathway may contribute to the occurrence of some post-colonoscopy cancers, as some precursor lesions, especially sessile serrated adenomas/polyps (SSA/Ps), are easily overlooked during colonoscopy (5, 6) and are more challenging to remove endoscopically (7). It is generally accepted that large, proximal or dysplastic (LPD) serrated polyps (SPs) purport significant risk for malignant transformation, whereas non-dysplastic small distal SPs do not (8-11). Some studies indicate that 31% of hyperplastic polyps and 27% of non-adenomatous polyps are missed during colonoscopy (12, 13) , which is consistent with a high variability in SP detection among endoscopists (i.e. ranging from 8% to 32% for all SPs, and from 1% to 18% for proximal SPs) (14, 15) . Taken together these findings highlight the need for improving detection of these lesions. To this end, Kahi In an attempt to clarify the risk profile associated with having ≥1 LPD SP, we firstly trained the endoscopists in the detection of non-polypoid colorectal lesions (24, 25), with focus on quality indicators (26), and subsequently examined these risk factors in a derivation cohort. We assumed that a priori estimation of the risk for having LPD SPs may heighten the vigilance of trainees and less experienced endoscopists in detecting such lesions, thereby reducing the high variability in SP detection. We finally developed and validated a simple risk score, i.e. the SP risk score, as a potential tool for improving the recognition of these lesions in routine practice.
Cancer Research. A questionnaire including demographics, smoking, body mass index (BMI), medication (i.e. use of aspirin / NSAIDs) and alcohol consumption, was administered to all eligible patients shortly after the colonoscopy. Inconsistent or missing data were verified through medical records and recorded as missing in case this information could not be retrieved. Patients who completed the questionnaire and provided informed consent were included in the final analyses. Smoking status was categorized into current, former or never and BMI classified in normal (i.e. <25 kg/m 2 ), overweight (i.e.
independent risk factors for having ≥1 LPD SP, using variables selected from the unadjusted logistic regression analyses (only variables with p-value ≤0.20 were included). The Hosmer-Lemeshow goodness-of-fit statistic was used to test reliability of the model.
Secondary aim of this study was to develop a SP risk score. Independent risk factors were incorporated into the risk score and for each risk factor, we assigned weight in the risk score by using the odds ratios from the adjusted logistic regression analyses and rounded it to the nearest whole number. Total scores were obtained by summing up the individual scores and the risks for having ≥1
LPD SP were calculated. Patients were subdivided into an average risk group (i.e. a priori defined as having a lower cumulative prevalence of LPD SPs than the previously proposed minimum detection target of 5% (16), and corresponding to a total score <5 points) and a high risk group (i.e. a priori defined as having a higher cumulative prevalence of LPD SPs than the suggested reference standard (16), and corresponding to a total score ≥5 points). In addition, the sensitivity and specificity of the risk score to identify patients with ≥1 LPD SP were calculated.
Validation of the SP risk score
For this purpose, a second cohort was prospectively accrued at our institution, comprising all consecutive patients undergoing colonoscopy from February 2010 to February 2012. In assembling this cohort we used a similar methodology (i.e. inclusion and exclusion criteria) as in the derivation cohort. Based on their total score, patients in the validation cohort were subdivided into the average risk group (i.e. corresponding to a total score <5 points) and high risk group (i.e. corresponding to a total score ≥5 points). Subsequently, the sensitivity and specificity of our risk score were calculated.
Statistical analysis
Means (standard deviations) and numbers (percentages) were used to describe continuous and categorical variables, respectively. Differences in continuous variables were analysed using the independent samples t-test and differences in categorical values using the 
RESULTS
In the derivation cohort, a total of 5246 colonoscopies were performed in 4753 patients. Of these, 1100 patients were excluded (<18 years, n=18; hereditary CRC syndrome, n=39; inflammatory bowel disease, n=356; personal history of CRC, n=172; prior colonic surgery n=81; unattainable for questionnaire, n=290; or newly diagnosed CRC at colonoscopy, n=144). Figure 1A illustrates the study diagram for the derivation cohort. A total of 3653 patients received the questionnaire, of whom 994 (27.2%) patients did not respond to the request (i.e. non-responders) and the remaining 2659 (72.8%) patients returned the questionnaire (i.e. responders). Responders were older (mean age [SD] 60 [14] 8.8%, p=0.510) or personal history of ≥1 SP (4.6% vs. 4.4%, p=0.765). A total of 316 (8.7%) nonparticipants (providing no informed consent, n=201; or returning a blank questionnaire, n=115) and patients receiving an examination by an endoscopist performing <50 colonoscopies (n=99) were also excluded resulting in a total of 2244 (61.4%) patients finally analyzed.
In the validation cohort, a total of 5883 colonoscopies were performed in 5266 patients. After exclusion, data from 2402 patients were finally examined. Figure 1B illustrates the study diagram of the validation cohort.
Quality indicators
Cecal intubation rates were 90.2% in symptomatic patients and 95.7% in asymptomatic patients, 30.6% had ≥1 adenoma and 15.9% ≥1 SP. As shown in Supplementary Table S1, in the derivation cohort, individual detection rates of ≥1 LPD SP ranged from 2.9% to 7.8% among gastroenterologists and from 2.3% to 12.1% among trainees.
Characteristics of patients in the derivation and validation cohort
Data from 2244 patients in the derivation cohort were finally analyzed. The mean (SD) age of the study population was 60 (14) 9.6% for screening indications. Table 1 depicts the baseline characteristics of the study population in the derivation and validation cohort subdivided according to presence of ≥1 LPD SP. In the derivation cohort, the prevalence of ≥1 LPD SP was higher in patients referred for surveillance versus symptoms or screening (13.3% vs. 5.3%, p<.001, 13.3% vs. 7.4%, p=0.045, respectively). No significant differences were found in prevalences of ≥1 LPD SP between patients referred for symptoms versus screening (5.3% vs. 7.4%, p=0.187). Patients with ≥1 LPD SP had significantly more adenomas and advanced adenomas compared to patients with non-dysplastic small distal or no SPs. Baseline characteristics regarding risk factors and the presence of ≥1 LPD SP in the derivation and validation cohort are presented in Table 2 .
Risk factors for the presence of ≥1 LPD SP and ≥1 adenoma in the derivation cohort
With regard to LPD SPs, results from the unadjusted and adjusted logistic regression analyses for the presence of ≥1 LPD SP are summarized in Table 3 . Variables associated with the presence of ≥1 LPD SP (i.e. p-value ≤0.20) in the unadjusted logistic regression analyses were incorporated into the adjusted logistic regression analyses. Adjusted logistic regression analyses showed that age >50 years (OR 2.2, 95% CI 1.3 -3.8, p=0.004), a personal history of ≥1 SP (OR 2.6, 95% CI 1.3 -4.9, p=0.005), current smoking (OR 2.2, 95% CI 1.4 -3.6, p=0.001) and non-daily or no aspirin use (OR 1.8, 95% CI 1.1 -3.0, p=0.016) were independent risk factors for the presence of ≥1 LPD SP.
Separate logistic regression analysis were performed using a cut-off value of ≥10 mm for large SPs, which did not significantly change the results.
With regard to adenomas, results from the unadjusted and adjusted logistic regression analysis for the presence of ≥1 adenoma are summarized in Supplementary Table S2 . Adjusted logistic regression analyses showed that age >50 years (OR 3.8, 95% CI 2.8 -5.2, p<.001), male gender (OR 1.8, 95% CI 1.5 -2.2, p<.001), a personal history of ≥1 adenoma (OR 2.8, 95% CI 2.0 -3.9, p<.001) and current smoking (OR 2.0, 95% CI 1.5 -2.7, p<.001) were all independent risk factors for the presence of ≥1 adenoma.
Development of the clinical SP risk score in the derivation cohort
Independent risk factors were incorporated into the SP risk score ( Table 3) . The Hosmer-Lemeshow goodness-of-fit statistic was p=0.279 for our model. ≥1 LPD SP per score category and corresponding 95% CI in the derivation cohort. Based on their total score, patients were subdivided into an average risk group (i.e. total score <5 points, n=1950) and a high risk group (i.e. total score ≥5 points, n=294). Prevalence of ≥1 LPD SP was 5.0% in the average risk group versus 14.6% in the high risk group (Table 4A) . Patients in the high risk group had a 3.2 fold increased odds of having ≥1 LPD SP than those in the average risk group. The sensitivity and specificity of our SP risk score to identify patients with ≥1 LPD SP were 30.5% (95% CI, 23.5% -38.5%) and 88.1% (95% CI, 86.6% -89.4%), respectively. Additional logistic regression analyses including different cut-off levels for age (i.e. ≥55 years; ≥60 years; ≥65 years, as well as age in decades) did not improve the sensitivity and specificity of our risk score. Figure 2B depicts the percentage of patients with ≥1 LPD SP per score category and corresponding 95% CI in the validation cohort. The prevalence of ≥1 LPD SP was 6.5% in the average risk group and 17.2% in the high risk group (Table 4B) . As compared to the average risk group, patients in the high risk group had a 3.0 fold increased odds of having ≥1 LPD SP. The sensitivity and specificity of the SP risk score were 33.2% (95% CI, 27.0% -40.0%) and 93.5% (95% CI, 92.4% -94.5%), respectively.
Validation of the SP risk score
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DISCUSSION
In this study, we found that 6.3% of all patients undergoing colonoscopy had ≥1 large, proximal or dysplastic SP. Age >50 years, a personal history of SPs, current smoking and non-daily/no aspirin use were independent risk factors for having LPD SPs. According to our SP score, patients in the high risk group had a 3.0 fold increased odds of having ≥1 LPD SP as compared to those in the average risk group. We suggest that pre-assessment of the clinical risk for having LPD SPs may heighten the vigilance of endoscopists in recognizing such lesions, and might reduce the observed variability in detection.
Several studies suggest that LPD SPs, in particular SSA/Ps, might contribute to the occurrence of post-colonoscopy cancers through a serrated neoplastic pathway (10, 35). It became clear that SPs often have a subtle endoscopic appearance, thereby explaining the operatordependent variation in their detection, ranging from 8% to 32% (14, 15) . This high variability in detection highlights the need for education and training, for which a systematic approach is needed, i.e. by means of video-training, computer-aided programs and learning from experts (14, 15) . In this context, the simple clinical score described in our study, might be a useful tool as we assume that a priori estimation of the risk for having LPD SPs may increase the awareness of the endoscopist to detect such lesions, through careful examination of the proximal colon (i.e. longer withdrawal time, twice examination or retroflexion, use of selective dye-based or digital chromoendoscopy or, perhaps additional tools, such as caps or endocuffs) (36).
Several studies have demonstrated that increasing age is associated with the presence of both adenomas and synchronous SPs (19, 21, 37, 38), whereas the association between age and SPs only remains controversial (19-21, 37, 38). In the current study, 51.1% of all patients with ≥1 LPD SP had ≥1 synchronous adenoma, at a mean (SD) age of 63 (11) years, suggesting that aging may increase the risk for having both LPD SPs and adenomas (19-21, 23). Some previous studies found an association between female gender and presence of SPs (9, 39) whereas others, including the current study, did not (40, 41). Most of these studies observing gender differences were retrospective in nature and based on histopathology data only. As the current study was prospective and based on standardized data registration, we assume that this setting might provide more accurate estimates of Some studies suggested that the risk factors for having SPs might differ from those associated with adenomas (19, 38). In our study, current smoking and increasing age were associated with both the presence of adenomas and SPs, whereas male gender was an independent risk factor for the presence of ≥1 adenoma only. An interesting finding of this study was that a personal history of ≥1 adenoma was associated with the presence of ≥1 adenoma, while a personal history of ≥1 SP was associated with the presence of ≥1 SP.
In the present study we found that patients with ≥1 LPD SP significantly more frequently had adenomas and advanced adenomas compared to patients with non-dysplastic small distal or no SPs, which is in line with previous data by us (5) and others (31, 32). Taken together, these data suggest that older age, prior history of SPs, current smoking and non-daily/no aspirin use, as well as presence of adenomas, may define a risk phenotype which is associated with synchronous LPD SPs. This observation is of relevance as it may highlight a subgroup of patients in whom multiplicity of lesions may require personalized surveillance, with regard to the frequency of examination or technique used (i.e. chromoendoscopy, either dye-based or digital-based techniques). In a previous study by our group, we found that presence of (advanced) adenomas during colonoscopic examination might be considered a 'red flag' for synchronous SPs (5). The SP risk score proposed in the current study extends these observations, by identifying an a priori risk profile for having ≥1 LPD SP.
Some methodological issues of this study need to be further addressed. As a strength, all endoscopists were familiarized with the recognition of non-polypoid colorectal lesions before commencing this study. This was essential, as nearly half of the SPs have a non-polypoid appearance (5, 6). We used a standardized endoscopic reporting system, including quality benchmarking, and applied the WHO histologic classification of SPs. As a potential limitation, in our Cancer Research. 
study, questionnaire responders were older than non-responders, in line with other Dutch surveys (34), and had more often colorectal lesions. As responders did not differ from non-responders with regard to gender, personal history of adenomas or SPs, we assume the differences found in prevalence of colorectal polyps may rather reflect the effect of aging than differences in response. To mitigate this source of bias logistic regression analyses were conducted adjusting for age. Second, as the questionnaire was distributed to the patients shortly after the colonoscopy, the possibility of a recall bias cannot be excluded. Nevertheless, other studies, employing a similar methodology as our study, found no differences in the reported risk factors among patients receiving the questionnaires before versus shortly after the colonoscopy (48) . Third, the SP risk score proposed in our study was developed in a real-life cohort, including symptomatic and asymptomatic patients, and hence generalizability to a screening population needs to be further examined. Fourth, the ability of identifying patients with ≥1 LPD SP, using the clinical SP risk score proposed in our study is only moderate with a sensitivity of 33% and specificity of 94%, albeit comparable with other clinical scores (49, 50). Finally, not unexpected, prevalences of ≥1 LPD SP and SSA/Ps without dysplasia were higher in the validation cohort than the derivation cohort. As the endoscopists and pathologists were unaware of the study hypothesis, we believe these findings rather reflect improvements in their learning curves through performance.
In conclusion, the present study indicates that age >50 years, a personal history of ≥1 SP, current smoking and non-daily/no aspirin use are all independent risk factors for having ≥1 LPD SP.
Risk pre-assessment of patients undergoing colonoscopy, using the simple clinical SP risk score proposed in our study, might enable identification of patients at higher risk of having ≥1 LPD SP.
Careful colonoscopic inspection in these patients, especially of the proximal colon, may reduce the currently observed variation among endoscopists in the detection of these lesions and finally improve the quality of examination.
